ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - Æxlishemjandi lyf - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - eplerenonum inn - filmuhúðuð tafla - 50 mg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

accord healthcare b.v. - fluorouracilum inn - stungulyf/innrennslislyf, lausn - 50 mg/ml

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratorios normon s.a. - amoxicillinum natríum; acidum clavulanicum kalíum - stungulyfs-/innrennslisstofn, lausn - 1000/200 mg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

upjohn eesv - eplerenonum inn - filmuhúðuð tafla - 50 mg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

upjohn eesv - eplerenonum inn - filmuhúðuð tafla - 25 mg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

opella healthcare france s.a.s. - triamcinolonum acetóníð - nefúði, dreifa - 55 míkróg/skammt

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

navamedic asa - cloxacillinum natríum - stungulyfs-/innrennslisstofn, lausn - 1 g

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

vital pharma nordic aps - dexamethasonum natríumfosfat - stungulyf/innrennslislyf, lausn - 4 mg/ml

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - ampicillinum natríum - stungulyfs-/innrennslisstofn, lausn